Cedars Sinai

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

K Health is a telehealth provider that allows users to get personalized health information based on the experiences of other patients. Users can check how people with the same symptoms have been diagnosed and treated by doctors free of charge, allowing them to make informed decisions about the next steps in the treatment. K claims that its service is better than Google as K considers personalized information such as age, gender, and medical history in presenting results. The app also allows users to consult a doctor’s opinion at a fee. For unlimited chats with a doctor, K charges USD 9 per month (or USD 19 for a one-off chat). Users can share their free K evaluations with a board-certified doctor, who will pick up after automated results. The doctor will diagnose, prescribe medicine, and advise users. &nbsp;As of <a href="https://khealth.com/primary-care/">July 2024</a>, the company charged users USD 49 per month for access to its healthcare services.The company acquired teletherapy platform Trusst in <a href="https://www.khealth.com/blog/about-k/k-health-acquires-trusst/">August 2021</a> to expand its mental health solutions, allowing K Health users to access on-demand text-based therapy and receive their medication at home, without the need for insurance or scheduling appointments.As of July 2024, the company noted that its platform’s database contains the data of about 2,000 patients, and is available across 48 states.Key customers and partnershipsMost recently, in <a href="https://sp-edge.com/updates/33651">September 2024</a>, K Health partnered with Hackensack Meridian Health, New Jersey's largest health network, to launch an AI-driven primary care service. HMH 24/7 began offering patients 24/7 access to Hackensack Meridian Health clinicians for primary care needs through their smartphones. The service integrated virtual and in-person care, using K Health's AI technology to streamline clinical processes and provide clinicians with comprehensive patient health profiles.The company partnered with medical and research center Mayo Clinic in <a href="https://sp-edge.com/updates/25160">January 2024</a> to build an AI solution aimed at preventing premature deaths caused by heart disease and stroke. Through the partnership, K Health's proprietary algorithms will be used to create an advanced AI-ECG (AI-enhanced electrocardiography) technology for risk assessment and remote patient monitoring. Mayo Clinic will provide de-identified patient data to refine the AI model used with the AI-ECG. This model will take into account factors such as age, gender, and health history to optimize treatment and predict risks.Prior to this, in <a href="https://sp-edge.com/updates/22600">July 2023</a>, K Health partnered with California-based primary care provider Cedars-Sinai, to incorporate K Health’s technology for virtual and urgent care services into Cedars-Sinai’s operations. Through the partnership, K Health and Cedars-Sinai began developing an app that helps patients connect with K Health’s AI and chat with doctors and nurses. The app, called Cedars-Sinai Connect, was launched in October 2023 for patients in California. Through the app, patients could access Cedars-Sinai experts for sick, chronic, and preventive care with 24/7 availability. The app uses AI technology developed by K Health and patients can pay per session or opt for a subscription fee for unlimited follow-up and remote visits.

Elaborate is a healthcare technology company that offers a solution to automate patient outreach and communication directly from electronic medical records (EMRs). The company's proprietary technology is integrated with EMRs through FHIR (Fast healthcare Interoperability Resources) or direct integration. Elaborate's clinical rule-based system codifies healthcare providers' clinical protocols to deliver personalized and vetted summaries of clinically significant findings to patients after appointments or medical procedures. This automated process eliminates the need for doctors to manually communicate with patients, resolving a significant pain point for healthcare providers and improving operational efficiency. By automating patient outreach, Elaborate's solution helps unlock additional patient capacity for healthcare organizations.

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Prometheus Biosciences is a biotechnology company engaged in the discovery, development, and commercialization of precision therapies and companion diagnostic products for autoimmune diseases. It is currently focused on inflammatory bowel disease (IBD). The company’s precision medicine platform Prometheus 360 uses data science and machine learning to identify new drug targets and unique disease biomarkers from large gastrointestinal bioinformatics databases.Prometheus’ drug candidate pipeline of treatments for IBD includes PRA023, the company’s lead program, which is an IgG1 humanized monoclonal antibody (mAb) that has been shown to block the tumor TL1A gene associated with both intestinal inflammation and fibrosis. PRA023 has the potential to improve outcomes for moderate-to-severe IBD patients who have increased TL1A expression. PRA023 is in Phase 3 clinical trials for the treatment of ulcerative colitis and Crohn’s disease. The company is also developing a companion diagnostic product in parallel to the drug, to identify patients more likely to respond to its treatment. Its second precision candidate, PRA052, an antibody to treat inflammatory bowel disease, received investigational new drug approval from FDA in Q3 2022 and initiated a Phase 1 clinical study. The company also has three programs in its drug development pipeline in the validation stage, led by another IBD drug that targets a member of the TNF superfamily.<a href="https://sp-edge.com/updates/17755">In April 2023 </a>, the company entered a definitive agreement with Merck, a multinational pharmaceutical company, in which the latter, through a subsidiary, will acquire Prometheus for a total cash consideration of USD 10.8 billion or USD 200 per share.Key partnerships and customersIn 2019, the company entered into a multi-target strategic collaboration with biopharma company Takeda to identify and develop targeted therapies for IBD as well as to develop companion diagnostics for these targets.Funding and FinancialsThe company began trading on Nasdaq under the ticker symbol “RXDX” in March 2021, raising USD 190 million at its initial public offering. In December 2022, the company raised USD 250 million via an underwritten public offering. The new funds along with its existing cash balance were allocated towards advancing the development of PRA023, PRA052, and its other R&amp;D programs, for working capital and general expenses.For 2022, the company reported a net loss of USD 141.8 million (up 57.1% YoY) and collaboration revenue of USD 6.8 million (up 119.4% YoY). <a href="https://sp-edge.com/updates/18502">In Q1 2023 </a>, net losses for the quarter increased 27.5% YoY to USD 40.8 million. It reported collaboration and license revenue of USD 1.1 million, compared with USD 3.9 million.

<div>
 
 Gemelli Biotech is a precision diagnostic startup focused on gastrointestinal (GI) diseases. It offers a non-invasive, at-home testing kit and analytics platform that identifies biomarkers and uses other information to detect and support the treatment of GI diseases. The firm offers two types of tests: trio-smart and ibs-smart.&nbsp;
 
 
 Trio-smart is a clinical breath test that measures various patient health parameters to understand their gut health. It supports the diagnosis of small intestinal bacterial overgrowth, intestinal methanogenic overgrowth,&nbsp; and excess hydrogen sulfide. The firm claims trio-smart is the only three-gas breath test that measures all of the primary fermented gasses produced in the gut: hydrogen, methane, and hydrogen sulfide. The firm&rsquo;s ibs-smart blood test was developed to support the diagnosis of post-infectious irritable bowel syndrome. Ibs-smart measures the levels of two validated IBS biomarkers, anti-CdtB, and anti-vinculin. Both tests can be ordered online through Gemelli&rsquo;s telehealth service or through the patient&rsquo;s healthcare provider.&nbsp;
 
 
 Key customers and partnerships
 
 
 Gemelli Biotech has teamed up with Cedars-Sinai Hospital in California, one of the top 10 hospitals in the US, for the development of diagnostics and therapeutics. In addition, the company partners with clinical laboratories globally to improve access to its ibs-smart.
 
 
 Funding and Financials
 
 
 In June 2022, the firm raised USD 19 million in a Series A funding round led by Ox Healthcare Partners. The fresh funds were allocated toward expediting its go-to-market strategy for trio-smart and ibs-smart. Additionally, the firm planned to expand its laboratory and manufacturing capacity as well as its sales and marketing across the US. It also intended to enter new markets in North Carolina and California.&nbsp;&nbsp;
 
</div>

Modern tools to train and motivate staff, and bridge emerging skill gaps.

EdTech: Corporate Learning

<div>
 
 Founded in 2018 by Dr. Alexander Young who created a virtual reality (VR) environment for medical training, Bristol-based Virti provides a VR training platform for enterprises. The platform can be used across mobile or desktop devices or VR/augmented reality (AR) headsets, and its analytics engine captures data across all three and provides objective and measurable feedback. The platform also contains a cloud-based, no-code simulation creation suite allowing organizations to build their own training modules. The platform is being used in the healthcare sector, and by universities, corporations, and public sector organizations.
 
 
 In June 2021, the company Virti raised USD 10 million in Series A funding for international growth, and research into new technologies. The company also announced the appointment of Oracle alumni, Kurt Kratchman and Mark Ashworth, as CRO and CFO/COO, respectively.
 
</div>

Imbuing emotion into human-digital interactions

Digital Humans

Virti is a corporate training company that leverages extended reality (XR), artificial intelligence, and gamification to enhance employee learning and skill retention. Founded in 2018 by Dr. Alexander Young, a former NHS trauma and orthopedic surgeon, Virti offers an end-to-end immersive learning platform accessible via mobile devices, desktops, and VR headsets. The company's cloud-based, no-code simulation creation suite allows organizations to build custom training modules that analyze employee performance using computer-vision AI and Natural Language Processing (NLP). Virti's technology focuses on improving both hard and soft skills, including crisis management, mindfulness, communication, and teamwork. The platform's deep learning technology reportedly improved training outcomes by up to 230% during the Covid-19 pandemic. Virti's approach aims to standardize and scale training across organizations and geographies, addressing the variability often found in on-the-job training. The company's technology has been deployed globally in healthcare settings, universities, corporations, and public sector organizations. Virti experienced significant growth during the pandemic, with revenue increasing by 978% as of July 2021. The company's innovative approach has garnered recognition, including being named one of TIME's best inventions of 2020 and among Fast Company's most innovative companies of 2021.

OneCell Diagnostics is a Precision Oncology Liquid Biopsy Diagnostics Company.

Jupiter BioVentures is a creation engine company that focuses on de-risking early-stage projects.

Elaborate is a clinical intelligence platform that eliminates physician burnout by automating inbasket tasks. Using patient's own health data, it streamlines workflows for results management, referral processing, and visit preparation, freeing clinicians of time-consuming administrative work. Trusted by health systems, academic medical centers, and multi-specialty groups, Elaborate decreases administrative burden, enhances compliance, and improves patient communication.

Syntho is an Amsterdam-based company revolutionizing the tech industry with AI-generated synthetic data. As the leading provider of synthetic data software, Syntho’s mission is to empower businesses worldwide to generate and leverage high-quality Synthetic Data at scale. Syntho solves data access problems with 3 main solutions: 1. AI-generated data for analytics: Enhance your AI data modeling with realistic, privacy-enhanced synthetic datasets that mimic the statistical patterns, relationships, and characteristics of original data, enabling accurate and reliable predictions 2. Smart de-identification: Protect sensitive information by removing or modifying personally identifiable information (PII), enhancing compliance with data privacy regulations 3. Test data management: Accelerate development cycles by creating, maintaining, and controlling diverse and representative test data for non-production environments, enabling comprehensive testing while safeguarding sensitive information

K Health is a data-driven digital primary care app that uses AI to deliver personalized primary care. The AI-powered health platform integrates data and creates a predictive model to enable its user to learn more about their personal well-being as well as help them better manage their health by comparing themselves to people with similar characteristics, gender, age, symptoms, and medical history, through a free symptom tracker. K Health is backed by Mangrove, 14W, Comcast Ventures, Lerer Hippeau, Primary Ventures, Max Ventures, The Box Group, GGV Capital, Valor Equity Partners, Kaiser Permanente, LTS Ventures, Atreides Ventures, PICO Partners, Marcy Venture Partners, and other New York and Israeli seed investors.

Censinet is a SaaS company in healthcare cybersecurity that provides a two-sided network platform for third-party risk assessments. It connects healthcare providers and their third-party vendors so they can efficiently manage and reduce risk in real time.

Fathom develops a coding automation platform that uses artificial intelligence to automatically review incoming charts and offers full-service coding services and comprehensive real-time audits, enabling medical operators to automate their coding and optimize their business.

Vita Therapeutics is a cell engineering company that develops life-transformative treatments. Vita utilizes induced pluripotent stem cell  technology to engineer specific cell types designed to replace those that are defective in patients.

Visby Medical is a diagnostics company that develops PCR-based diagnostic tests for the detection of infectious diseases. The company develops a device platform that aims to redefine the way an illness is tested and treated. They believe that by taking a human-centric, technology-first approach to device development and they can create tools that are both highly accurate and delightful to use.

Gemelli is a biotechnology company that specializes in the microbiome, and IBS diagnostics. It strives to achieve a thriving global family of healthy individuals by unlocking the potential of the microbiome. The company is driven by its mission is to support the discovery of novel diagnostics and therapeutics for the human microbiome by bringing biotechnology innovations to market in a fiscally responsible and socially conscious way.  The company was founded in 2018 and headquartered in North Carolina, United States.

Dieta helps people who suffer from IBS (estimated 45M in USA) to improve their symptoms by providing personalized digestive health recommendations. Our mobile application captures high-resolution data on their diet, bowel movements, medications, and other factors, and then uses machine learning to generate precise recommendations for their path to relieving symptoms and improving quality of life.

Virti is an award-winning, immersive, enterprise learning solution for healthcare and beyond. Virti allows for creation and cross-platform distribution of interactive, immersive (VR, AR and MR) educational content and provides analytics that intelligently predict how a user will perform under pressure before entering a real environment. Virti uses research into cognitive decision-making under pressure and an immersive video platform combined with augmented reality to help professionals prepare for real-life high-pressure environments including surgery, sports, emergency response and military training.

Prometheus Biosciences, Inc., former Prometheus Laboratories, Inc., a specialty pharmaceutical company, engages in developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. It markets and promotes Entocort EC, a glucocorticosteroid, which is indicated for the induction and maintenance of clinical remission in mild to moderately active Crohn's disease involving the ileum and/or the ascending colon. It has an agreement to acquire rights to LOTRONEX tablets, which is used in female patients with diarrhea-predominant irritable bowel syndrome; and an agreement to develop and commercialize COLAL-PRED, a development-stage product for the treatment of gastrointestinal diseases or other applications. The company also sells other branded drugs, including Imuran for use as an adjunct for the prevention of rejection in kidney transplantation and the management of active rheumatoid arthritis, Helidac Therapy for use together with an H2 antagonist for the eradication of helicobacter pylori bacteria, and Ridaura for the management of rheumatoid arthritis. In addition, Prometheus Laboratories sells a generic formulation of mercaptopurine, which is approved as maintenance therapy for acute lymphatic leukemia as part of a combination regimen through third-party distributors. Further, it provides diagnostic testing services, including specific immunoassays to detect and differentiate diseases, pharmacogenetic testing, and drug metabolite monitoring; and tests that assist physicians in using and monitoring thiopurine drugs and the detection, diagnosis, or treatment of celiac disease, lactose intolerance, and other related disorders. Prometheus Laboratories, Inc. was founded in 1995 and is headquartered in San Diego, California.

Clinician Nexus provides health systems, schools, and students with a transparent, people-centered platform that facilitates better clinical rotation management, from start to finish.

Tasso is revolutionizing blood-based diagnostics by placing the user at the center of the diagnostics process. Patients are able to sample their own blood in the comfort of their home with a device that is safe, simple, and convenient.

CardioCube was a physician-led startup on a mission to make healthcare affordable and accessible through technology. Our membership-based virtual healthcare service provides employees at companies of all sizes with unlimited virtual access to doctors and care management powered by Voice AI. CardioCube's technology was acquired by Voxel S.A., a diagnostics and healthcare IT systems provider (https://voxel.pl/).

Wellist operates an online platform that connects patients to local services in the greater Boston area. The company’s platform allows families and patients to find daily support services that range from rides and treatment to meal delivery, home cleaning, acupuncture, and more. Its platform also allows users to build and publish a registry of needed services to share with loved ones, as well as allows them to track activities and thank the loved ones for their support. Wellist was founded in 2013 and is headquartered in Boston, Massachusetts, United States.

Emulate is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.

Capricor Therapeutics is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of cell and exosome-based therapeutics for the treatment and prevention of diseases.  Its  CAP-1002 is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and COVID-19.  The company was founded in 2005 and is headquartered in Los Angeles, California.

Health Care DataWorks is a provider of business intelligence solutions, empowers healthcare organizations to improve their quality of care and reduce costs. Through its pioneering KnowledgeEdge™ product suite, including its enterprise data model, analytic dashboards, applications and reports, Health Care DataWorks delivers an Enterprise Data Warehouse necessary for hospitals and health systems to effectively and efficiently gain deeper insights into their operations.  The Enterprise Data Warehouse developed by Health Care DataWorks includes a unified data model and bundled software, hardware and support that can be implemented at a fraction of the cost and time it would take hospital systems to build their own. The benefit to hospitals and health systems of all sizes is they are provided with a broad and seamless view of financial, administrative, clinical and research data for easy analysis and timely decision making.  When hospital and health systems implement the Health Care DataWorks KnowledgeEdge Enterprise, they can make better business decisions, improve patient care and enhance their operating efficiency.

Cedars-Sinai is a non-profit, academic, community-centric medical center in Los Angeles, California. Recognized internationally, Cedars-Sinai brings together top healthcare professionals collaborating to provide exceptional patient care.

Cedars-Sinai is a non-profit medical center that provides primary and specialty care services. The company provides in-person care services and virtual consultations via Cedars-Sinai Connect. The company’s in-care facilities include a full suite of testing and treatment facilities, while its platform facilitates consultations for primary, urgent, and mental healthcare and second opinions on diagnoses from other healthcare providers. Cedars-Sinai additionally carries out research initiatives, functioning as a clinical research organization to operate clinical trials across various fields, including stem cell biology, immunology, and genetics.

Cedars-Sinai

Cedars Sinai study questions aggressive prostate cancer treatment for some men

OneCell Diagnostics

Celesta Capital

Tenacity Ventures

Singularity Venture Partners

Eragon

Jupiter BioVentures

Mayo Clinic

Eshelman Ventures

Alexandria Venture Investments

Mission BioCapital

Bioventure Partners

The CU Healthcare Innovation Fund

Vault Fund

Fox Ventures

Elaborate

Companies developing B2B software solutions for patient engagement, care navigation, practice management, and electronic health records integration to facilitate telehealth services for healthcare providers.

Syntho

K Health

Mangrove Capital Partners

Valor Equity Partners

Max Ventures

BoxGroup

Primary Ventures

PICO Venture Partners

Marcy Venture Partners

LTS Investments

Primary care through virtual consultations for general health-related concerns using a digital platform or mobile app.

Censinet

Rex Health Ventures

MemorialCare Innovation Fund

Ballad Ventures

Schooner Capital

LRVHealth

HLM Venture Partners

Excelerate Health Ventures

Fathom

Lightspeed Venture Partners

Alkeon Capital

Tarsadia Investments

Founders Fund

ApolloMD

Inflect Health

Vita Therapeutics

Cambrian Biopharma

Solve FSHD

TEDCO

Riptide Ventures

Visby Medical

Lightrock

Pitango VC

Artiman Ventures

Blue Water Life Science Advisors

Gemelli Biotech

Blue Ox Healthcare Partners

Carolina Angel Network

CerraCap Ventures

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Ping An Global Voyager

NDCapital

Blue Water Life Science Fund

Healthcare of Ontario Pension Plan (HOOPP)

Nissim Capital

Dieta Health

Techstars

Verissimo Ventures

Headwater Ventures

Virti

IQ Capital

Learning and engagement tools include platforms that offer adaptive learning, gamification, immersive learning, and microlearning solutions that can be used by enterprises for the delivery of learning content.

Prometheus Biosciences

Eventide

RTW Investments

Nestle

Perceptive Advisors

Irving Investors

Point72

Cormorant Capital

Cowen Healthcare Investments

AGI Partners

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Valo Ventures

J-Ventures

Clinician Nexus

Hyde Park Venture Partners

Sofia Fund

Service Provider Capital

Great North Ventures

Tasso

Vertical Venture Partners

Cedars-Sinai is a non-profit medical center that provides primary and specialty care services. The company provides in-person care services and virtual consultations via Cedars-Sinai Connect. The company’s in-care facilities include a full suite of testing and treatment facilities, while its platform facilitates consultations for primary, urgent, and mental healthcare and second opinions on diagnoses from other healthcare providers. Cedars-Sinai additionally carries out research initiatives, functioning as a clinical research organization to operate clinical trials across various fields, including stem cell biology, immunology, and genetics.As of <a href="https://www.cedars-sinai.org/about.html">August 2024</a>, the company had over 40 in-person care facility locations, providing treatment for multiple specialties. It also had a staff size of over 4,500 physicians and nurses and had 1,500 research projects in progress.Key customers and partnershipsIn <a href="https://www.techtarget.com/virtualhealthcare/news/366596905/Cedars-Sinai-Expands-Virtual-Care-Access-with-New-mHealth-App#:~:text=K%20Health%20and%20Cedars%2DSinai,funding%20round%20for%20the%20company.">October 2023</a>, Cedars-Sinai and K Health partnered to launch Cedars-Sinai’s virtual care platform, Cedars-Sinai Connect. Through the partnership, Cedars-Sinai was able to begin providing virtual care to patients in California for sick, chronic, and preventive care.In <a href="https://www.fiercehealthcare.com/providers/tia-marks-largest-partnership-date-cedars-sinai-open-womens-health-clinics-la#:~:text=Women's%20health%20startup%20Tia%20has,modern%20medical%20home%20for%20women.%22">January 2023</a>, Cedars-Sinai partnered with women’s health startup Tia to expand access to primary and specialty care for women in Los Angeles. Through the partnership, Tia and Cedars-Sinai enabled access to physical, mental, and reproductive healthcare for more than 100,000 women.In <a href="https://www.alignmenthealth.com/Newsroom/Press-Releases/Alignment-Healthcare-Partners-With-Cedars-Sinai-in#:~:text=ORANGE%2C%20Calif.%2C%20Aug.,%2C%202022%2C%20pending%20regulatory%20approval.">August 2021</a>, Cedars-Sinai partnered with Alignment Healthcare to join Alignment’s partner network. Through the partnership, 1.5 million Medicare-eligible seniors of Alignment Healthcare gained access to Cedars-Sinai’s physicians.

Nice healthcare is a virtual and in-home primary care provider that offers a suite of healthcare services to small and medium-sized businesses, including primary care, mental health therapy, and physical therapy. Nice healthcare operates on a fixed monthly fee per member model, allowing employees to access unlimited care without additional out-of-pocket costs. The company provides virtual consultations through its app, as well as in-home visits for physical exams, lab tests, and X-rays.&nbsp;As of <a href="https://www.nice.healthcare/locations">August 2024</a>, Nice Healthcare was operating in 12 states: Arizona, Colorado, Idaho, Iowa, Minnesota, Nebraska, Nevada, New Mexico, Oregon, Utah, Washington, and Wisconsin. The company's services covered <a href="https://www.nice.healthcare/the-nicessities/three-categories-of-primary-care#:~:text=Only%204%25%20of%20our%20patients,with%20Nice%20may%20look%20like.">over 95%</a> of issues patients typically discuss with their clinicians, with <a href="https://www.nice.healthcare/the-nicessities/three-categories-of-primary-care#:~:text=Only%204%25%20of%20our%20patients,with%20Nice%20may%20look%20like.">only 4%</a> of patients being referred to external specialists. The company employs nurse practitioners, registered nurses, physician assistants, and medical assistants to deliver care.As of <a href="https://www.nice.healthcare/the-nicessities/three-categories-of-primary-care">August 2024</a>, Nice healthcare offered 35 free labs and physical tests as well as in-home imaging services and prescribed over 550 free medications that could be picked up at over 60,000 pharmacies nationwide or delivered to patients' homes.&nbsp;Key customers and partnershipsIn <a href="https://www.prnewswire.com/news-releases/getlabs-and-nice-healthcare-partner-to-expand-access-to-virtual-healthcare-services-and-at-home-lab-testing-301813668.html">May 2023</a>, Nice Healthcare announced a partnership with Getlabs, a provider of at-home diagnostic collections. This collaboration aimed to expand access to in-home healthcare services and lab testing, allowing Nice healthcare patients to benefit from a more comprehensive suite of diagnostic tests.

Nice Healthcare

Amicomed is a cloud-based Software-as-a-Service (SaaS) platform which provides blood pressure monitoring services. It collects blood pressure data of patients from at-home devices, applies algorithms, and assesses the fluctuations in the blood pressure. Physicians can be connected and provided with blood pressure data of their patients in order to facilitate their workload, enabling more personalized management of patients regarding medication and lifestyle indications.Amicomed can also recommend actionable and personalized lifestyle interventions such as daily diet and exercises via virtual coaching.

Amicomed

Winston is a men’s health telemedicine platform that treats common issues impacting men such as sexual problems, hair loss, acne, and cold sores. Winston allows patients to consult doctors, place orders for prescription drugs, and offers free delivery to the homes of patients.The Toronto-based company aims to avoid men deferring doctor visits or withholding sensitive information. The consultation fee is covered by the provincial health plan, but the prescriptions are billed to the customer.

Winston

Dialogue is a leading virtual care and well-being platform that provides comprehensive health services to organizations and their employees. Founded in 2016, the company offers an integrated health platform that centralizes various health and wellness programs in a single application, accessible <a href="https://www.dialogue.co/en/blog/dialogues-2023-year-in-review#:~:text=Serving%2015%25%20of%20the%20Canadian%20population&amp;text=How%3F,aspects%20of%20their%20well%2Dbeing.">24/7/365</a>. Dialogue's services include primary care, mental health support, employee assistance programs, and wellness initiatives. As of <a href="https://www.dialogue.co/en/blog/dialogues-2023-year-in-review#:~:text=Serving%2015%25%20of%20the%20Canadian%20population&amp;text=How%3F,aspects%20of%20their%20well%2Dbeing.">December 2023</a>, Dialogue's platform was accessible to around 6 million Canadians, representing approximately 15% of the country's population.The company saw significant growth in <a href="https://www.dialogue.co/en/blog/dialogues-2023-year-in-review#:~:text=Serving%2015%25%20of%20the%20Canadian%20population&amp;text=How%3F,aspects%20of%20their%20well%2Dbeing.">December 2023</a>, with a 34% increase in consultations across all aspects of well-being in 2023 compared to the previous year. Mental health consultations, in particular, saw a 67% increase.&nbsp;In <a href="https://www.newswire.ca/news-releases/dialogue-enters-into-license-agreement-with-sun-life-u-s--824463104.html">July 2023</a>, Dialogue was acquired by Sun Life for an undisclosed sum, expanding its reach beyond Canada. This expanded service reach was estimated to cover an additional 600,000 members in the US. The acquisition was completed in <a href="https://www.sunlife.com/en/newsroom/news-releases/announcement/sun-life-completes-the-acquisition-of-dialogue-canadas-premier-health-and-wellness-virtual-care-platform/123792/">October 2023</a>, with Dialogue continuing to operate as a standalone entity.Key customers and partnershipsThe company has partnerships with major insurers and benefits providers to offer its services as part of employee benefits packages. Additionally, the company noted that, as of <a href="https://www.dialogue.co/en/pricing">August 2024</a>, it worked with over 50,000 companies across Canada to provide its services to employees.

Dialogue

Grin offers telemedicine and remote monitoring services for orthodontic needs such as braces and teeth straightening. Patients can conduct self-scans (using a Grin device made available to patients in collaboration with 3M) which can be connected to their smartphones and share the feed with orthodontists to access dental solutions. The company plans to go to a subscription-based model after the pandemic. The app also encourages patients to have a 40-second check monthly and share the scan with a dentist in order to allow patients to regularly maintain their dental hygiene.Grin is the only Telehealth disruptor covered on the hub that provides virtual orthopaedic consultations.Funding and financialsIn April 2021, the New York-based teledental platform concluded a seed funding of USD 14 million, and the funds will be allocated to develop additional functionalities by building out its technology. The proceeds will also be used to scale up its team, expand its geographic footprint, and add doctors to the company’s orthodontic partner network.

Grin

Real-time collection of patients’ health-related data using any remote patient monitoring device combined with general telemedicine services to reduce readmission rates.

A platform that facilitates the transmission of patient data to different locations for further evaluation and interpretation by medical specialists.

A digital platform that offers specialty care services to address the specific needs of a patient or demographic, including consultations where patients are generally reluctant to meet practitioners face-to-face.

Companies that use GenAI as a core part of their product offering for Telehealth

IoT is used by most telehealth providers to operate virtual services

All telehealth players are involved in digital health via virtual offerings

Industry players offer varying degrees of personalization for each target audience

Some players offer technology and platforms to healthcare providers, converting physical-only services into virtual services

Specific telehealth offerings focus on diversity and inclusion, providing care to LGBTQ+ or BIPOC populations

Generative AI is used to streamline administrative tasks such as clinical note-taking

PROMINENT_CATEGORY

<div>
 
 The California health system, Cedars-Sinai, has expanded its virtual healthcare platform, Cedars-Sinai Connect, by introducing a Spanish version of the app for parents of children aged three to 17 and Spanish-speaking adults. The AI-powered platform provides access to healthcare providers for urgent issues such as colds, rashes, flu, and coughs on-demand or via scheduled visits. Spanish-speaking users can navigate the app in their native language to access primary care services for managing chronic conditions.
 Cedars-Sinai, a non-profit medical center, provides both in-person and virtual healthcare services. The organization's in-care facilities include a comprehensive suite of testing and treatment facilities. Meanwhile, their Cedars-Sinai Connect platform caters to primary, urgent, and mental health care services. Cedars-Sinai also engages in numerous research initiatives and functions as a clinical research organization conducting trials across various fields, such as stem cell biology, immunology, and genetics. As of April 2024, the organization operated over 40 in-person care facilities offering treatment in over 17 specialties. It had a staff size exceeding 4,500 physicians and nurses and was managing 1,500 ongoing research projects.
 
</div>

Cedars-Sinai

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless